The authors conclude that the therapeutic effect of MG-132 was mediated mainly by the inhibition of NF-κB activation but also involved the peripheral nervous system, and they mentioned new-generation PIs as potential novel pharmacotherapy for RA. Here, NFKB1 is linked to rheumatoid arthritis.